Para-Aminobenzenesulfonamide Therapy in Experimental Type III Pneumococcal Pneumonia

Abstract

Conclusion

P-aminobenzenesulfonamide given orally to rats suffering from experimental Type III (“420” strain) pneumococcal pneumonia reduced the mortality and increased the survival-period. The effectiveness of this treatment varied inversely with the interval Ijetween infection and initial treatment, and with the magnitude of the infecting dose. The treated rats which succumbed showed less bacteremia and a lower incidence of peritonitis than the untreated ones which succumbed. The course and extent of the pneumonia was not appreciably affected. Treatment apparently enables many of the animals to survive the associated toxemia which is commonly fatal to similarly infected, but untreated, rats.